How does stem cell therapy help kidney disease?

MSCs reduce renal inflammation, protect kidney cells from further damage, promote repair of damaged nephrons, and reduce fibrosis. This can slow CKD progression and improve kidney filtration rates.

Can stem cell therapy delay the need for dialysis?

For patients with moderate CKD (stages 2-4), MSC therapy may help preserve remaining kidney function and potentially delay the need for dialysis. Early intervention provides the best opportunity for kidney preservation.

What kidney function improvements can be expected?

Patients may see improvements in GFR (glomerular filtration rate), reduced proteinuria, stable or improved creatinine levels, and better overall kidney function markers within 3-6 months of treatment.

Stem Cell Therapy for Kidney Disease: Regenerative Nephrology

Research on stem cell therapy for chronic kidney disease, IgA nephropathy, and diabetic nephropathy. How MSC treatment may slow renal decline and support kidney function.

Stem Cell Mechanisms in Renal Repair

Chronic kidney disease (CKD) involves progressive nephron loss and renal fibrosis — tubular cell death, glomerular scarring, and replacement of functional tissue with fibrotic matrix (driven by TGF-β1). MSC therapy targets three mechanisms: (1) anti-fibrotic paracrine action — MSCs suppress TGF-β1 signalling, activate hepatocyte growth factor (HGF), and reduce interstitial fibrosis; (2) tubular cell protection — MSCs secrete IGF-1 and EGF that protect surviving proximal tubular cells from apoptosis; (3) immune modulation — reducing the T-cell-driven interstitial nephritis that accelerates progression in IgA nephropathy and lupus nephritis.

Which Kidney Conditions Show the Best Response?

Published evidence is strongest for: IgA nephropathy (30–50% reduction in proteinuria in several series), diabetic nephropathy (slowed eGFR decline, reduced proteinuria), lupus nephritis (addressed under SLE studies), and acute kidney injury (AKI recovery). CKD stages 2–4 benefit most; stage 5 (pre-dialysis/dialysis) shows limited structural improvement but may improve residual function and quality of life. Patients on dialysis for >12 months are generally not candidates for meaningful renal recovery.

Kidney Disease Treatment Protocol

StemCell Longevita's renal programme delivers 2–3 IV infusion sessions of 50–100 million WJ-MSCs over 5–7 days. Pre-treatment evaluation includes full renal panel (eGFR, creatinine, urea, electrolytes, urine protein:creatinine ratio), renal ultrasound, and nephrologist review. Follow-up at 3, 6, and 12 months tracks eGFR trajectory, proteinuria, and blood pressure. Patients maintain their existing nephrology care alongside our programme.

Frequently Asked Questions

How does stem cell therapy help kidney disease?: MSCs reduce renal inflammation, protect kidney cells from further damage, promote repair of damaged nephrons, and reduce fibrosis. This can slow CKD progression and improve kidney filtration rates.
Can stem cell therapy delay the need for dialysis?: For patients with moderate CKD (stages 2-4), MSC therapy may help preserve remaining kidney function and potentially delay the need for dialysis. Early intervention provides the best opportunity for kidney preservation.
What kidney function improvements can be expected?: Patients may see improvements in GFR (glomerular filtration rate), reduced proteinuria, stable or improved creatinine levels, and better overall kidney function markers within 3-6 months of treatment.

Stem Cell Therapy for Kidney Disease: Regenerative Nephrology

Stem Cell Mechanisms in Renal Repair

Which Kidney Conditions Show the Best Response?

Kidney Disease Treatment Protocol

Frequently Asked Questions

Transform Your Health with Regenerative Medicine in Istanbul